"Stable Business Foundation" Hanmi Science and Hanmi Pharmaceutical Receive 'AA-' Rating from NICE Investors Service

[Financial News] Hanmi Group announced on the 13th that its holding company Hanmi Science and operating company Hanmi Pharmaceutical have received a credit rating of 'AA-' (Stable) from NICE Investors Service.
Based on the interim financial statements for this year, Hanmi Science was awarded the highest rating among major domestic pharmaceutical holding companies. NICE Investors Service cited the strong business competitiveness and financial stability of its core affiliate Hanmi Pharmaceutical, as well as stable control over key subsidiaries such as Onlinepharm and JVM, as the main reasons for the rating.
Hanmi Pharmaceutical was upgraded by two notches from its previous 'A' rating to 'AA-' in recognition of improved business performance and financial structure. This marks the first upgrade in two years since the regular evaluations by NICE Investors Service and Korea Investors Service in June 2023.
NICE Investors Service pointed to the sales growth of major product lines, which rose from 1.1 trillion won in 2020 to 1.5 trillion won last year, continued investment in research and development (R&D), and excellent portfolio management capabilities as grounds for the rating, concluding that the companies will maintain a stable business foundation.
A Hanmi Group representative stated, "We will focus on developing innovative new drugs and discovering future growth engines based on a more transparent and sound governance structure," adding, "Furthermore, we are committed to responsible management so that we can become a trusted company for shareholders, consumers, and all stakeholders in society."


kaya@fnnews.com Choi Hye-rim Reporter